 |
      
|
|
|
|
|
|||||
|
|
November 9, 2001
U.S. patent issued for Neurochem.
New Patent for Epilepsy Program Expands on Company's Central Nervous System (CNS) Platform
Neurochem Inc. (TSX : NRM) announces the issuance of a patent in the U.S. No. 6,306,909
relating to the Company's Epilepsy program. The U.S. patent was issued to Neurochem's research
collaborators in the field of Epilepsy at Queen's University. About Epilepsy
Epilepsy is a neurological disorder characterized by seizures involving a loss of normal
movement, disrupted consciousness and convulsions. It is a devastating condition, which is
complicated by the multiplicity of its causal factors. Worldwide there is an estimated
45 million patients suffering from Epilepsy. Neurochem has identified a large unmet clinical
need for new therapeutic options for Epilepsy that offer both a cure for the disease and
relief of the symptoms. About Neurochem
Neurochem is an industry leader in the development of therapeutic drugs and diagnostic
tools for central nervous system and amyloid-related diseases associated with aging. The
Company has built a strong product pipeline by developing a novel, proprietary series of
compounds that inhibit the formation, deposition and toxic effects of amyloid fibrils
within the body. Neurochem's therapeutic programs target Alzheimer's Disease, Epilepsy,
Systemic Amyloidosis, Diabetes Type II and Hemorrhagic Stroke (due to Cerebral Amyloid
Angiopathy). Neurochem is using a multi-pronged approach towards the development of
pharmaceuticals for Alzheimer's Disease, including glycosaminoglycans (GAGs) mimetics,
a vaccine, an anti-inflammatory and neuroprotective approaches as well as the creation of
a diagnostic imaging tool. The Company has advanced to date three drug candidates to
clinical trials: Alzhemed™, for the treatment of Alzheimer's Disease,
Fibrillex™, for the orphan disease Secondary Amyloidosis, and Cerebril™, for
Hemorrhagic Stroke. At present, the Company employs over 70 people and is located
in Saint-Laurent, Canada (www.neurochem.com).
All of the statements contained in this news release, other than statements of fact which
are independently verifiable at the date hereof, are forward-looking statements. Such
statements, based as they are on the current expectations of management, inherently involve
numerous risks and uncertainties, known and unknown. Some examples of known risks are: the
impact of general economic conditions, general conditions in the pharmaceutical industry, changes
in the regulatory environment in the jurisdictions in which Neurochem does business, stock
market volatility, fluctuations in costs, and changes to the competitive environment due to
consolidation or otherwise. Consequently, actual future results may differ materially from
the anticipated results expressed in the forward-looking statements.
For further Information, please contact: |
 |
|
 |
|
Our site is best viewed with IE4+ at a resolution of 1024×768. |
|
